Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia

20091,350 citationsJournal Articlebronze Open Access

Authors

Parameswaran Nair · St. Joseph’s Healthcare Hamilton

Márcia Margaret Menezes Pizzichini · St. Joseph’s Healthcare Hamilton

Melanie Kjarsgaard · McMaster University

Mark D. Inman · McMaster University

Ann Efthimiadis · McMaster University

Emílio Pizzichini · St. Joseph’s Healthcare Hamilton

Frederick E. Hargreave

Abstract

Mepolizumab reduced the number of blood and sputum eosinophils and allowed prednisone sparing in patients who had asthma with sputum eosinophilia despite prednisone treatment. (ClinicalTrials.gov number, NCT00292877.)

Topics & Keywords

Asthma and respiratory diseases Eosinophilic Esophagitis Eosinophilic Disorders and Syndromes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 360, Issue 10, pp. 985-993

DOI: 10.1056/nejmoa0805435

Field-Weighted Citation Impact: 65.79